- Home
- SDGR vs BEAM Comparison
SDGR vs BEAM Comparison
Compare SDGR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDGR
- BEAM
- Stock Information
- Founded
- SDGR 1990
- BEAM 2017
- Country
- SDGR United States
- BEAM United States
- Employees
- SDGR N/A
- BEAM N/A
- Industry
- SDGR Biotechnology: Pharmaceutical Preparations
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SDGR Health Care
- BEAM Health Care
- Exchange
- SDGR Nasdaq
- BEAM Nasdaq
- Market Cap
- SDGR 1.6B
- BEAM 1.9B
- IPO Year
- SDGR 2020
- BEAM 2020
- Fundamental
- Price
- SDGR $21.74
- BEAM $27.50
- Analyst Decision
- SDGR Buy
- BEAM Buy
- Analyst Count
- SDGR 10
- BEAM 10
- Target Price
- SDGR $32.90
- BEAM $47.67
- AVG Volume (30 Days)
- SDGR 594.0K
- BEAM 1.0M
- Earning Date
- SDGR 11-12-2024
- BEAM 11-05-2024
- Dividend Yield
- SDGR N/A
- BEAM N/A
- EPS Growth
- SDGR N/A
- BEAM N/A
- EPS
- SDGR N/A
- BEAM N/A
- Revenue
- SDGR $193,348,000.00
- BEAM $349,643,000.00
- Revenue This Year
- SDGR N/A
- BEAM N/A
- Revenue Next Year
- SDGR $26.50
- BEAM $10.82
- P/E Ratio
- SDGR N/A
- BEAM N/A
- Revenue Growth
- SDGR N/A
- BEAM 328.73
- 52 Week Low
- SDGR $16.67
- BEAM $20.84
- 52 Week High
- SDGR $38.00
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- SDGR 53.17
- BEAM 56.65
- Support Level
- SDGR $20.33
- BEAM $27.02
- Resistance Level
- SDGR $21.96
- BEAM $29.53
- Average True Range (ATR)
- SDGR 0.97
- BEAM 1.73
- MACD
- SDGR -0.15
- BEAM 0.10
- Stochastic Oscillator
- SDGR 42.80
- BEAM 59.63
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.